Our Team

Jeffrey P. Norenberg
Chief Executive Officer

Dr. Jeffrey Norenberg is a biotech executive and leader in radiopharmaceutical innovation. As Co-Founder and CEO of iSeek Biopharma, he leads strategy, fundraising, and clinical development of innovative molecular imaging agents and radioligand therapies. With over 35 years of experience spanning academia, industry, and regulatory science, he has secured over $26 million in research funding and led multiple first-in-human trials.

Previously, he held leadership roles at Clarity Pharmaceuticals, Invicro, and the University of New Mexico. He has authored 150+ peer-reviewed publications and holds 12 U.S. patents. Dr. Norenberg also leads the National Association of Nuclear Pharmacies and the Massachusetts Nuclear Medicine & Radiopharmaceutical Council.

He earned his PharmD from the University of Washington and PhD in Molecular Medicine from Erasmus University Rotterdam. His leadership is shaping iSeek Biopharma into a market leader in precision diagnostics and targeted oncology.

Boudewijn J. Krenning, MD, PhD
Chief Medical Officer

Dr. Boudewijn Krenning is a physician-scientist and cardiologist specializing in non-invasive imaging and radiopharmaceutical research. As Chief Medical Officer at iSeek Biopharma, he leads clinical and regulatory strategy, advancing the company’s radiopharmaceutical pipeline from preclinical stages to early-phase trials. His scientific journey began at the University of New Mexico with research on targeted alpha radionuclide therapy using 213Bismuth. He earned his PhD at Erasmus MC, focusing on 3D echocardiographic quantification of cardiac function. Dr. Krenning’s academic work now centers on molecular imaging of cardiovascular disease. At iSeek Biopharma, he combines clinical expertise with scientific leadership, overseeing protocol development, regulatory submissions, and strategic collaborations. He is a key figure in shaping clinical governance and serves as a trusted advisor to investors, regulators, and partners. His work reflects a commitment to innovation and patient-centered care.

James F. Kronauge, PhD
Chief Scientific Officer

Dr. James F. Kronauge is a leading expert in radiopharmaceuticals with over 40 years of experience across academia, biotech, and pharma. As Co-Founder and Chief Scientific Officer of iSeek Biopharma, he oversees scientific strategy, regulatory planning, and early-stage manufacturing. He is known for his pioneering work in radiochemistry, including the development of Cardiolite™, Azedra™, and the 82Sr/82Rb CardioGen® Generator.

At iSeek, Dr. Kronauge leads Chemistry, Manufacturing, and Controls (CMC), ensuring regulatory compliance and innovation. His career includes leadership roles at Hesperos, CytoSite, Tomopath, Invicro, and Molecular Insight Pharmaceuticals. He also served as Assistant Professor of Radiology at Harvard Medical School.

Dr. Kronauge holds a Ph.D. in Inorganic Chemistry from MIT and a B.S. in Chemistry from Kent State University. His technical expertise and strategic vision continue to position iSeek Biopharma at the forefront of precision diagnostics and targeted radiotherapeutics.

Eric P. Krenning, MD, PhD, FRCP
Senior Advisor

Professor Eric P. Krenning is a world-renowned expert in Nuclear and Internal Medicine, celebrated for his pioneering work in radiopharmaceuticals and theranostics. He earned his MD and PhD from Erasmus University Rotterdam and led the Department of Nuclear Medicine at Erasmus MC, where he revolutionized neuroendocrine tumor (NET) diagnostics and therapy. His contributions include the development of OctreoScan®, Lutathera®, and Lysakare®. Dr. Krenning’s translational research advanced peptide receptor imaging and therapy globally. He founded Cyclotron Rotterdam BV, enhancing radiopharmaceutical infrastructure in Europe. With over 500 publications and an H-index of 110, he is an honorary member of the Royal College of Physicians, EANM, and ENETS. As Co-founder and Senior Advisor at iSeek Biopharma, he continues to shape the future of targeted diagnostics and therapeutics, offering unmatched clinical and scientific expertise.

George Glatcz
Chief Commercial Officer

George Glatcz is Chief Commercial Officer at iSeek Biopharma, bringing over 30 years of experience in pharmaceutical, biotech, radiopharmaceutical, and healthcare marketing. He leads commercial strategy, go-to-market planning, and asset value maximization through partnerships and licensing. George has scaled companies from $50 million to over $1 billion in revenue, leveraging his background as a healthcare practitioner and executive to align product development with market needs. Prior roles include President/Chief Strategy Officer at Michael J. Hennessy & Associates, President/COO at Ritzman Pharmacy, and Head of Medical Communications at Amplity Health. He also held leadership positions at Monsanto/Searle, Boehringer Mannheim, and DuPont Merck, where he helped launch Cardiolite™, a major cardiovascular imaging agent. Recognized as one of the Most Inspiring People in Life Sciences, he’s received the DuPont Marketing Excellence Award and served on multiple boards. His leadership is key to iSeek Biopharma’s growth, market entry, and strategic success.

J. Gordon Chan
Director, iSeek Biopharma AU Pty Ltd

Gordon Chan is a radiopharmaceutical scientist and pharmacist with more than forty years of experience in radiochemistry, GMP manufacturing, Quality Assurance, and clinical operations. As Director of iSeek Biopharma AU, he plays a pivotal role in advancing the company’s strategic initiatives and driving operational execution in Australia. Gordon leads the integration of scientific, regulatory, and quality systems to enable timely, compliant, and scalable execution of iSeek’s development programs from manufacturing through first-in-human studies.

Gordon holds a Bachelor of Pharmacy and Graduate Diploma in Hospital Pharmacy from the Victorian College of Pharmacy and served among the inaugural members of the Radiopharmaceutical Science Certification Panel of the Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM). Previously, he established Australia’s first centralized radiopharmacy and PET facility at Austin Health (Melbourne) and contributed to the registration of more than ten radiopharmaceuticals.